John Baldoni

John Baldoni has over 42 years of experience in the pharmaceutical industry, specializing in platform technologies and guiding the development of small molecules, biopharmaceuticals, and cell and gene therapies from discovery through commercialization. He spent 29 years at GSK R&D—including 11 years as Senior Vice President of Platform Technology and Science on its Executive Leadership Team, overseeing roughly 40% of R&D headcount—and in 2017 launched GSK’s first AI‑driven drug discovery unit; after retiring in 2019, he served as Chief Technology Officer of a stealth AI‑enabled drug discovery startup. As an independent consultant, John advises both emerging, cutting‑edge drug and diagnostic companies and established firms seeking strategic innovation; he has participated in the research and development of scores of commercial products and conceived the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium—now ARA—while also serving as the inaugural Chair of the Alliance for Artificial Intelligence in Healthcare’s Executive Committee. He holds a PhD in biological chemistry from Penn State University (1980).